Time to Explore Preventive and Novel Therapies for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 10, 2012, Pages 1479-1487

  Sengsayadeth, Salyka M ^a   Srivastava, Shivani ^b   Jagasia, Madan ^a   Savani, Bipin N ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; BOS; CGVHD

Indexed keywords

AZATHIOPRINE; AZITHROMYCIN; BORTEZOMIB; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; EVEROLIMUS; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; GAMMA INTERFERON; IMATINIB; INFLIXIMAB; METHOXSALEN; METHYLPREDNISOLONE; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLIN G; PLACEBO; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ADD ON THERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; B LYMPHOCYTE; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS T CELL LYMPHOMA; DONOR; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSPNEA; EXTRACORPOREAL PHOTOPHERESIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GRAFT VERSUS HOST REACTION; HUMAN; HYPERGLYCEMIA; IMMUNOTHERAPY; LOW DRUG DOSE; LUNG BIOPSY; LUNG INJURY; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OPPORTUNISTIC INFECTION; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCLERODERMA; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; BRONCHIOLITIS OBLITERANS; CHRONIC DISEASE; COMBINED MODALITY THERAPY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOTRIENE ANTAGONISTS; LUNG; LUNG TRANSPLANTATION; PHOTOPHERESIS; PRACTICE GUIDELINES AS TOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 84866158028     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.03.008     Document Type: Review

References (75)

1. Savani B.N., Griffith M.L., Jagasia S., Lee S.J. How I treat late effects in adults after allogeneic stem cell transplantation. Blood 2011, 117:3002-3009.
2. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
3. Savani B.N., Montero A., Wu C., et al. Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:223-230.
4. Savani B.N., Montero A., Srinivasan R., et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:1261-1269.
5. Williams K.M., Chien J.W., Gladwin M.T., Pavletic S.Z. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009, 302:306-314.
6. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
7. Todd J.L., Palmer S.M. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest 2011, 140:502-508.
8. Chien J.W., Martin P.J., Gooley T.A., et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003, 168:208-214.
9. Yi T., Chen Y., Wang L., et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009, 114:3101-3112.
10. Skert C., Damiani D., Michelutti A., et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant 2009, 44:729-737.
11. Srinivasan M., Flynn R., Price A., et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 2012, 119:1570-1580.
12. Wolf D., von Lilienfeld-Toal M., Wolf A.M., et al. Novel treatment concepts for graft-versus-host disease. Blood 2012, 119:16-25.
13. Greinix H.T., Pohlreich D., Kouba M., et al. Elevated numbers of immature/transitional. Biol Blood Marrow Transplant 2008, 14:208-219.
14. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009, 113:3865-3874.
15. Chien J.W., Duncan S., Williams K.M., Pavletic S.Z. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-verus-host disease. Biol Blood Marrow Transplant 2010, 16(1 Suppl):S106-S114.
16. Forslw U., Mattsson J., Gustafsson T., Remberger M. Donor lymphocyte infusion may reduce the incidence of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1214-1221.
17. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981, 57:267-276.
18. Ratjen F., Rjabko O., Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant 2005, 36:135-138.
19. Hildebrandt G.C., Fazekas T., Lawitschka A., et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011, 46:1283-1295.
20. Bashoura L., Gupta S., Jain A., et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:63-67.
21. Bergeron A., Belle A., Chevret S., et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2007, 39:547-553.
22. Celik M.R., Lederer D.J., Wilt J., et al. Tacrolimus and azathioprine versus cyclosporine and mycophenolate mofetil after lung transplantation: a retrospective cohort study. J Heart Lung Transplant 2009, 28:697-703.
23. Borro J.M., Bravo C., Sol A., et al. Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome. Transplant Proc 2007, 39:2416-2419.
24. Snell G.I., Valentine V.G., Vitulo P., et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006, 6:169-177.
25. Groetzner J., Wittwer T., Kaczmarek I., et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006, 81:355-360.
26. Gottlieb J., Szangolies J., Koehnlein T., Golpon H., Simon A., Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008, 85:36-41.
27. Yates B., Murphy D.M., Forrest I.A., et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005, 172:772-775.
28. Gerhardt S.G., McDyer J.F., Girgis R.E., Conte J.V., Yang S.C., Orens J.B. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003, 168:121-125.
29. Vos R., Vanaudenaerde B.M., Ottevaere A., et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer?. J Heart Lung Transplant 2010, 29:1358-1368.
30. Vos R., Vanaudenaerde B.M., Verleden S.E., et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011, 37:164-172.
31. Khalid M., Al Saghir A., Saleemi S., et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005, 25:490-493.
32. Daneshpouy M., Socie G., Lemann M., Rivet J., Gluckman E., Janin A. Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood 2002, 99:3033-3040.
33. Daneshpouy M., Facon T., Jouet J.P., Janin A. Acute flare-up of conjunctival graft-versus-host disease with eosinophil infiltration in a patient with chronic graft-versus-host disease. Leuk Lymphoma 2002, 43:445-446.
34. Jacobsohn D.A., Schechter T., Seshadri R., Thormann K., Duerst R., Kletzel M. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation 2004, 77:1096-1100.
35. Or R., Gesundheit B., Resnick I., et al. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation 2007, 83:577-581.
36. Verleden G.M., Verleden S.E., Vos R., et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transpl Int 2011, 24:651-656.
37. Norman B.C., Jacobsohn D.A., Williams K.M., et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 2011, 46:1369-1373.
38. Lucid C.E., Savani B.N., Engelhardt B.G., et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant 2011, 46:426-429.
39. Greinix H.T., van Besien K., Elmaagacli A.H., et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis-results of a crossover randomized study. Biol Blood Marrow Transplant 2011, 17:1775-1782.
40. Foss F.M., Gorgun G., Miller K.B. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant 2002, 29:719-725.
41. Jagasia M.H., Savani B.N., Stricklin G., et al. Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biol Blood Marrow Transplant 2009, 15:1288-1295.
42. Couriel D., Hosing C., Saliba R., et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?. Biol Blood Marrow Transplant 2006, 12(1 Suppl 2):37-40.
43. Morrell M.R., Despotis G.J., Lublin D.M., Patterson G.A., Trulock E.P., Hachem R.R. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010, 29:424-431.
44. Majhail N.S., Schiffer C.A., Weisdorf D.J. Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006, 12:789-791.
45. Olivieri A., Locatelli F., Zecca M., et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009, 114:709-718.
46. Svegliati S., Olivieri A., Campelli N., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007, 110:237-241.
47. Johnson R.J., Raines E.W., Floege J., et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992, 175:1413-1416.
48. Magro L., Catteau B., Coiteux V., Bruno B., Jouet J.P., Yakoub-Agha I. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008, 42:757-760.
49. Stadler M., Ahlborn R., Kamal H., et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood 2009, 114:3718-3719. author reply 3719-3720.
50. Shimabukuro-Vornhagen A., Hallek M.J., Storb R.F., von Bergwelt-Baildon M.S. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009, 114:4919-4927.
51. Kharfan-Dabaja M.A., Cutler C.S. Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol 2011, 93:578-585.
52. Kim S.J., Lee J.W., Jung C.W., et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 2010, 95:1935-1942.
53. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
54. Okamoto M., Okano A., Akamatsu S., et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006, 20:172-173.
55. Lorillon G., Robin M., Meignin V., et al. Rituximab in bronchiolitis obliterans after haematopoietic stem cell transplantation. Eur Respir J 2011, 38:470-472.
56. Iacono A.T., Johnson B.A., Grgurich W.F., et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006, 354:141-150.
57. Groves S., Galazka M., Johnson B., et al. Inhaled cyclosporine and pulmonary function in lung transplant recipients. J Aerosol Med Pulm Drug Deliv 2010, 23:31-39.
58. Hayes D., Zwischenberger J.B., Mansour H.M. Aerosolized tacrolimus: a case report in a lung transplant recipient. Transplant Proc 2010, 42:3876-3879.
59. Busca A., Locatelli F., Marmont F., Ceretto C., Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007, 82:45-52.
60. Chiang K.Y., Abhyankar S., Bridges K., Godder K., Henslee-Downey J.P. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002, 73:665-667.
61. Yanik G.A., Mineishi S., Levine J.E., et al. Soluble tumor necrosis factor receptor: Enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011, [Epub ahead of print].
62. Blanco B., Prez-Simn J.A., Snchez-Abarca L.I., et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006, 107:3575-3583.
63. Lemy A., Toungouz M., Abramowicz D. Bortezomib: a new player in pre- and post-transplant desensitization?. Nephrol Dial Transplant 2010, 25:3480-3489.
64. Neumann J., Tarrasconi H., Bortolotto A., et al. Acute humoral rejection in a lung recipient: reversion with bortezomib. Transplantation 2010, 89:125-126.
65. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009, 114:3956-3959.
66. Rabitsch W., Deviatko E., Keil F., et al. Successful lung transplantation for bronchiolitis obliterans after allogeneic marrow transplantation. Transplantation 2001, 71:1341-1343.
67. Calhoon J.H., Levine S., Anzueto A., Bryan C.L., Trinkle J.K. Lung transplantation in a patient with a prior bone marrow transplant. Chest 1992, 102:948.
68. Sano Y., Date H., Nagahiro I., Aoe M., Shimizu N. Living-donor lobar lung transplantation for bronchiolitis obliterans after bone marrow transplantation. Ann Thorac Surg 2005, 79:1051-1052.
69. Arai S., Sahaf B., Jones C., et al. 283: Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin (TLI-ATG) nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD. Biol Blood Marrow Transplant 2007, 13:103.
70. Sahaf B., Chen G., Boiko J., et al. 391: Rituximab infusion after allogeneic HCT prevents donor B cell reconstitution and alloimmunity one year post transplant. Biol Blood Marrow Transplant 2008, 14:142.
71. Aue G., Lindorfer M.A., Beum P.V., et al. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 2010, 95:329-332.
72. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
73. Alousi A.M., Uberti J., Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 2010, 51:376-389.
74. Armand P., Gannamaneni S., Kim H.T., et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008, 26:5767-5774.
75. Pulsipher M.A., Wall D.A., Grimley M., et al. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol 2009, 147:691-699.